Primary Objectives:~Phase Ib~• To determine the safety, tolerability and recommended phase II dose (RP2D) of SNDX-5613 in combination with oral decitabine/cedazuridine (ASTX727) and venetoclax for patients with acute myeloid leukemia (AML).~Phase II~• To assess the efficacy of SNDX-5613 in combination with ASTX727 and venetoclax for patients with AML.~Secondary Objectives~• To assess overall survival, event-free survival and duration of response.~Exploratory Objectives~• To evaluate molecular and cellular markers that may be predictive of antitumor activity and/or resistance.
Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML) or those with a mixed phenotype acute leukemia with a myeloid phenotype (MPAL).~Part 2 of this study is to learn if the dose of study drugs found in Part 1b can help to control AML/MPAL